Melvin Au

Melvin Au serves as the Business and Technology Development Principal at the National University Cancer Institute, Singapore, since September 2023. Prior to this role, Melvin was the Senior Manager for Analytical Development at Tessa Therapeutics Pte Ltd from September 2018 to April 2023, specializing in analytical and process development utilizing a Quality by Design approach for Cell Therapy. Melvin's previous experience includes serving as a Senior Scientist in Analytical Development at Takeda, where expertise in vaccine development was honed, and as a Senior Manager and Technical Lead at Clearbridge Accelerator, focusing on strategic planning for product and business development. Early career roles involved positions as a Scientist I at Novartis, contributing to early drug discovery efforts, and as a Medical Technologist at Singapore General Hospital, leading monoclonal antibody projects. Melvin holds a Bachelor of Applied Science in Biotechnology from the National University of Singapore and a Graduate Certificate in IP Law from IP Academy Singapore/NUS.